Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Inclusion Criteria : * Participant is aged ≥ 6 months to \< 36 months. * Participant is considered to be in good health on the basis of reported medical history and limited physical examination. * Participant is available for the duration of the study. * Parent/guardian is willing and able to provide informed consent. * Parent/guardian is willing and able to meet protocol requirements. Exclusion Criteria : * Reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine. * Previous history of influenza vaccination or documented history of influenza infection. * An acute illness with or without fever (temperature \> 100.4 °F rectal) in the 72 hours preceding enrollment in the trial (defer enrollment). * Clinically significant findings in vital signs or review of systems (investigator judgment; defer or exclude). * Participation in any other clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study. * Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth. * Personal or immediate family history of congenital immune deficiency. * Developmental delay, neurologic disorder, or seizure disorder. * Chronic medical, congenital, or developmental disorder. * Known human immunodeficiency virus (HIV)-positive mother. * Prior history of Guillain-Barré syndrome. * Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine. * Any vaccination in the 14 days preceding enrollment in the study or scheduled between Visit 1 and Visit 3.